Castle Biosciences SEC Filings

Dimensional Fund Advisors LP reported beneficial ownership of 1,474,089 shares of Castle Biosciences Inc common stock, representing 5.1% of the class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership while reporting sole voting power over 1,447,712 shares and sole dispositive power over 1,474,089.

The Schedule 13G indicates the position is held in the ordinary course of business and not to influence control of the issuer. The filing was signed by Dimensional's Global Chief Compliance Officer on 10/09/2025.

Castle Biosciences (CSTL) director and CEO Derek J. Maetzold reported a sale of 1,339 shares of common stock on 10/02/2025 at a weighted-average price of $22.58 per share under a pre-existing Rule 10b5-1 trading plan adopted on 5/08/2025. After the transaction, the filing shows 64,327 shares held directly by the reporting person and multiple indirect holdings across family and trust vehicles, including trusts named in the filing.

The sale was executed in multiple trades at prices ranging from $22.31 to $23.14, and the filer said they will provide detailed trade-by-trade information upon request. The Form 4 is a routine Section 16 disclosure showing an insider sale conducted under an affirmative-defense plan rather than an ad-hoc transaction.

Derek J. Maetzold, President & Chief Executive Officer and a director of Castle Biosciences, sold 1,339 shares of Castle Biosciences common stock on 09/17/2025 under a preexisting Rule 10b5-1 plan at a weighted-average price of $21.971 per share. After the sale, the filing reports Mr. Maetzold directly or indirectly beneficially owns multiple blocks of shares held in various trusts, with specific reported holdings including 65,666 shares directly and several trust holdings (for example, 52,923; 44,986; multiple 3,615–3,618 blocks; and larger grantor retained annuity trusts of 85,959; 18,718; and 44,323).

The Form 4 explains the sale was effected through multiple trades at prices ranging from $21.860 to $22.085 and that the transactions were executed pursuant to a 10b5-1 plan adopted May 8, 2025. The form is signed by an attorney-in-fact on behalf of the reporting person.

Derek J. Maetzold, President & Chief Executive Officer and a director of Castle Biosciences, Inc. (CSTL), sold 1,339 shares of the issuer's common stock on 09/02/2025 under a Rule 10b5-1 trading plan adopted May 8, 2025. The transaction executed in multiple trades produced a weighted-average sale price of $23.93 per share. Following the sale, the filing reports 67,005 shares held directly and multiple indirect trust holdings disclosed by name and amount, including 52,923 shares held by The Maetzold Descendants 2020 Trust and other family trusts and grantor retained annuity trusts. The Form 4 was signed by attorney-in-fact Frank Stokes on 09/04/2025.

Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), reported the sale of 12,677 shares of the company's common stock in a transaction executed at a weighted-average price of $22.019 per share. The reported sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and, after the transaction, the reporting person beneficially owned 141,116 shares. The filing discloses that the sale occurred in multiple trades at prices ranging from $22.000 to $22.145 and that the reporting person will provide detailed trade-level information on request.

Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc. (CSTL), reported the sale of 18,007 shares of the issuer's common stock on 08/27/2025. The sales were executed in multiple trades at prices ranging from $21.24 to $21.94, with a reported weighted-average sale price of $21.69. Following the reported disposition, Oelschlager beneficially owned 153,793 shares, held directly. The Form 4 was signed by an attorney-in-fact, Frank Stokes, on 08/29/2025. The filer affirms availability to provide trade-level price and share details upon request.

Form 144 filing for Castle Biosciences, Inc. (CSTL) shows a proposed Rule 144 sale of 18,007 shares of common stock through J.P. Morgan Securities LLC on 08/27/2025 on NASDAQ with an aggregate market value of $384,449.45. The shares stem from restricted stock units granted by the issuer: 10,171 RSUs acquired 03/04/2025 and 7,836 RSUs acquired 08/08/2025, with payment characterized as compensation. No sales by the reporting person in the past three months are reported. The filer attests there is no undisclosed material adverse information.

Castle Biosciences (CSTL) submitted a Form 144 disclosing a proposed sale of 25,355 shares of common stock through J.P. Morgan Securities LLC on or about 08/27/2025 on the NASDAQ. The filing reports an aggregate market value of $541,329 against 29,008,281 shares outstanding. The shares originated from two Restricted Stock Unit grants received as compensation: 7,837 units acquired on 08/09/2024 and 17,518 units acquired on 12/09/2024, with payment/vesting dates matching acquisition dates. The filer certifies no undisclosed material adverse information and indicates this is a LIVE filing.

Castle Biosciences director and CEO Derek J. Maetzold reported a sale of 1,339 shares of Castle Biosciences common stock executed under a Rule 10b5-1 plan at a weighted-average price of $20.04 per share. The filing states the sale was executed in multiple trades with prices ranging from $20.00 to $20.10 and that the reporting person will provide trade-level details upon request.

Following the reported transaction, the form discloses the reporting persons remaining direct and indirect beneficial ownership across trusts and vehicles, including 68,344 shares held directly and multiple indirect holdings (for example, 52,923, 44,986, 85,959, and others) held through family and grantor retained annuity trusts. The sale was made pursuant to a pre-established written plan adopted in May 2025.